Eli Lilly's Lepodisiran Achieves 94% Reduction in Genetic Cholesterol in Phase 2 Trial

The siRNA-based drug shows promise as the first potential treatment for lipoprotein(a), a major cardiovascular risk factor, with Phase 3 trials now underway.

• Phase 2 trial results presented at the American College of Cardiology meeting reveal lepodisiran reduced lipoprotein(a) (Lp(a)) levels by up to 94% after two doses over one year.
• The trial, involving 320 participants, confirmed the drug's safety with no serious adverse events reported.
• Lepodisiran works by targeting messenger RNA to inhibit the production of apolipoprotein(a), a key component of Lp(a).
• High levels of Lp(a), a genetic risk factor for cardiovascular disease, affect 1.4 billion people globally, with no currently approved treatments.
• Phase 3 trials are now underway to determine if lowering Lp(a) translates to reduced cardiovascular events such as heart attacks and strokes, with patient enrollment expected to conclude this year.

7 Articles

NBC News Semafor Gizmodo Interesting Engineering New York Post The Hill